Search

Displaying results 1571 - 1580 of 3735 in total
  1. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter catabolism via

  2. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission

  3. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors
  4. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.[FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into...

  5. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    Depemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug. Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence. Depemokimab blocks interleukin-5 (IL-5)...

  6. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    These results are consistent with the transport of glisoxepide via the transport system for the unconjugated bile acid cholate. [A31819,A31820]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  7. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen].

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  8. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Follitropin

    go.drugbank.com/drugs/DB00066
    ApprovedInvestigational

    However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but

  10. Drug

    PF-03654746

    go.drugbank.com/drugs/DB12201
    Investigational

    PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.